SUMMARY Peritoneal dialysis effluent collected from patients undergoing continuous ambulatory peritoneal dialysis had no opsonic activity against Staphylococcus epidermidis and contained low concentrations of IgG and C3 (roughly equal to those found in 0 5% normal human serum). An intravenous immunoglobulin preparation that showed no opsonic activity against the same organism, on its own or when added to balanced salt solution or peritoneal dialysis fluid, showed good activity when combined with peritoneal dialysis effluent. This was probably due to the presence of low concentrations of C3 in the effluent as prior heat inactivation at 56°C for 30 minutes eliminated any opsonic activity in the immunoglobulin-dialysis effluent mixture. Examination of a range of immunoglobulin preparations showed that their opsonic activity for S epidermidis in the absence of complement varied considerably. Luminol dependent chemiluminescence was unsatisfactory as a method for detecting complement independent immunoglobulin mediated opsonisation. Intravenous immunoglobulin preparations may be useful in boosting the peritoneal defences of those patients undergoing continuous ambulatory peritoneal dialysis (CAPD) who suffer from repeated intraperitoneal infections.
Peritonitis caused by Staphylococcus epidermidis is a major complication of continuous ambulatory peritoneal dialysis (CAPD).' Persistent or recurrent infection may oblige CAPD to be stopped.
Treatment of peritonitis entails the rapid introduction of large volumes of peritoneal dialysis fluid into the peritoneal cavity. This has been shown to impair phagocytic defences by diluting the amounts of immunoglobulin and complement opsonins.23 Keane and Peterson4 suggested that peritonitis could be managed by enhancing local phagocytic defences. They showed that the addition of purified immunoglobulin to dialysis fluid or effluent increased the opsonic activity of both against S epidermidis.
Standard immunoglobulin preparations prepared from human plasma by the classical Cohn alcohol fractionation method have good biological activity. They contain mainly IgG with little IgM (or IgA). They also contain polymeric aggregates,. however, which make them unsuitable for intravenous administration and probably for intraperitoneal use. Immunoglobulin preparations suitable for intravenous use Accepted for publication 5 March 1986 have been prepared using enzyme treatment, chemical modification treatment with polyethylene glycol, or alcohol fractionation at pH 4.5 6
Several of these preparations are now commercially available. In this study we examined the opsonic activity of a range of these for S epidermidis when added to balanced salt solution, peritoneal dialysis fluid, and peritoneal dialysis effluent. Our observation that most intravenous immunoglobulin preparations produced maximal opsonic effect when combined with the low concentrations of complement present in dialysis effluent was confirmed using 05% normal human serum and antibody free baby rabbit serum as alternative complement sources. 48 (6) 49 (7) IgG(l mg/ml)
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14 (3) 15 ( (Table 2 ). An intravenous imumunoglobulin preparation (Sandoglobulin) was used as a source of opsonin. When added to either HBSS or peritoneal dialysis fluid, in concentrations ranging from 1 mg/ml to 10 mg/ml, it failed to enhance the uptake of S epidermidis in comparison with 2-5% normal human serum, which gives optimal opsonisation of S epidermidis (Table 3) . When added to peritoneal dialysis effluent with a low IgG and C3 content (5-0 mg/dl and 0-45 mg/dl, respectively), however, which itself was a poor opsonin, the uptake of S epidermidis was enhanced (Table 4) . Heating the effluent at 56°C for 30 minutes removed this effect, suggesting that the key factor in the dialysis was the low concentration of C3 in the unheated effluent, which, together with the added immunoglobulin, provided an effective opsonic mixture. Table 5 shows the opsonic activity of 14 immunoglobulin preparations, representing four different products, against S epidermidis, compared with that of 2-5% normal human serum. Two conclusions can be drawn from these results. First, the various preparations differed in their capacity to opsonise S epidermidis in the absence of complement: there was also variation between different batches of the same product. Second, with purified immunoglobulin, luminol dependent chemiluminescence did not seem to be an effective method of monitoring opsonic activity. Even when the microscopic assay showed good bacterial uptake, chemiluminescence remained poor.
The importance of complement for opsonisation was shown by examining the opsonic activity of six immunoglobulin preparations in the presence or absence of complement, provided either by 0-5% or Peterson4 also showed that an immunoglobulin preparation enhanced the uptake of S epidermidis when added either to peritoneal dialysis fluid or effluent, and raised the possibility that passive immunisation of the peritoneal cavity might reduce the incidence of peritonitis in patients undergoing CAPD.
We felt that this observation was worth pursuing more systematically. Given the limitations of standard immunoglobulin preparations for anything other than intramuscular administration, we decided to use intravenous immunoglobulin preparations.
Our initial experiments entailed an intravenous immunoglobulin preparation made by alcohol separation at pH 4 (Sandoglobulin). In contrast to Keane and Peterson,4 we found that this showed no opsonic activity against S epidermidis when added to HBSS or dialysis fluid. It had good opsonic activity, however, when combined with dialysis effluent, which itself was not opsonic for the organism. As heat inactivation of the effluent destroyed the opsonic activity of the immunoglobulin-effluent mixture we concluded that opsonisation resulted from a combination of the high IgG concentration and low complement value.
Testing 14 batches of intravenous immunoglobulin, representing four different preparations, showed that two had good opsonic activity against S epidermidis, as measured by a microscopical phagocytic assay, in the absence of complement. When complement was added either as 0 5% normal human serum or peritoneal dialysis effluent, however, four of six preparations tested were good opsonins: interestingly, luminol dependent chemiluminescence was unsatisfactory as an assay for opsonisation by immunoglobulin alone, the amounts seen being uniformly low. When complement was added chemiluminescence correlated well with the microscopical assay of phagocytosis.
Our results show that intravenous immunoglobulin preparations can enhance phagocytosis in the peritoneal cavity. Batches and preparations will need to be screened for optimal opsonic activity, but their safety remains to be proved and they are expensive. As a result, if any clinical work is to be done we feel that careful patient selection will be vital. 
